Kari Grønås • 1964 • Oslo • 6 roles • 9 shareholdings

This website uses cookies to enhance the user experience.

Roles

Management

Name	Role	Total operating income	Total equity	Shares
K K OG K AS	Managing Director/CEO	5,524,443	22,477,695	50 % directly

Boards

Name	Role	Total operating income	Total equity	Shares
K K OG K AS	Board Member	5,524,443	22,477,695	50 % directly
L LUNGEKREFTFORENINGEN	Chairman	-	-	-
U ULTIMOVACS ASA	Board Member	-	309,373,000	-
O ONCOINVENT ASA	Board Member	5,790,000	54,931,000	-
I IMMUNOQUEST THERAPEUTICS AS	Board Member	-	30,000	-

Last update: Sep 12, 2024

Related industries2

Human health and social work activities
Professional, scientific and technical activities

Direct relationships5

ØS
Øystein Soug1969
ONCOINVENT ASA
HS
Henrik Schüssler1963
ULTIMOVACS ASA
ES
Eddy Sigfred Grønset1967
LUNGEKREFTFORENINGEN
AP
Anders Pablo Kapstad1964
IMMUNOQUEST THERAPEUTICS AS
OK
Ole Kristian Hjelstuen1962
IMMUNOQUEST THERAPEUTICS AS

Shares owned by Kari Grønås

Name	Share class	Total operating income	Total equity	Share
K K OG K AS	Ordinære aksjer	5,524,443	22,477,695	50 % directly
C CAEDO ONCOLOGY AS		0	14,416,685	6.94 % indirectly
S SERCA PHARMACEUTICALS AS		3,571,688	16,391,412	1.51 % indirectly
A AUGERE MEDICAL AS		761,740	14,822,199	1.02 % indirectly
N NOWWELL AS		4,746,705	5,686,904	0.54 % indirectly
N NOWWELL FLOW TECHNOLOGY AS		244,148	-1,058,712	0.54 % indirectly
N NOWWELL DEVELOPMENT AS		-	-	0.54 % indirectly
N NOWWELL HOLDING AS		-	-	0.54 % indirectly
N NOWWELL SOLUTION AS		-	-	0.54 % indirectly

Limited to direct ownership positions of 0.5% or more.

Last update: May 24, 2024